Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
Latest Information Update: 11 May 2022
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions
- Sponsors Helixmith
- 22 Nov 2021 New trial record
- 09 Nov 2021 Results published in the Media Release